Four large randomized controlled trials studied omalizumab vs. placebo in allergic asthma using serum IgE as part of their inclusion criteria, and all demonstrated significant reduction in asthma exacerbations, inhaled corticosteroid use, and improvement in symptom burden [10,11,12,13]. Here, IGHE is linked to asthma.